Braveheart Bio registers Phase 3 trial of BHB-1893 in non-obstructive hypertrophic cardiomyopathy
The study plans to enroll an estimated 600 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, beginning in December 2026 and aiming for primary completion in December 2029. Its main purpose is to find out whether BHB-1893 works better than placebo in adults with non-obstructive hypertrophic cardiomyopathy.
Primary source
ClinicalTrials.gov registry record, November 18, 2026
BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Read the source: BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation